Search Results - "Bartels, Prisca"

Impact of Postoperative Chemotherapy in Patients with Gastric/Gastroesophageal Adenocarcinoma Treated with Perioperative Chemotherapy by Ballhausen, Alexej, Bartels, Prisca, Iacovella, Ines, Hoegner, Anica, Lorusso, Alessandro, Bichev, Dmitry, Daum, Severin, Thuss-Patience, Peter

“…Perioperative chemotherapy is the standard of care for patients undergoing curative resection for gastroesophageal adenocarcinoma. However, less than 50% of…”
Get full text

Prognostic Relevance of Weight and Weight Loss during Multimodal Therapy for Oesophagogastric Tumours by Lorusso, Alessandro, Bichev, Dmitry, Högner, Anica, Bartels, Prisca, Ballhausen, Alexej, Treese, Christoph, Biebl, Matthias, Thuss-Patience, Peter

“…The prognostic meaning of weight loss (WL) during standard treatment for operable oesophagogastric cancer is still unclear. The aim of this study is to analyse…”
Get full text

Ramucirumab, avelumab and paclitaxel (RAP) as second line treatment in esophagogastric adenocarcinoma: Final results of the phase 2 RAP trial (AIO-STO-0218) by Thuss-Patience, Peter C., Högner, Anica, Goekkurt, Eray, Stahl, Michael, Kretzschmar, Albrecht, Goetze, Thorsten Oliver, Stocker, Gertraud, Reichardt, Peter, Kullmann, Frank, Pink, Daniel, Bartels, Prisca, Jarosch, Armin, Hinke, Axel, Paschold, Lisa, Stein, Alexander, Binder, Mascha

“…4032 Background: The addition of immune checkpoint inhibitors to chemotherapy has improved outcomes in patients (pts) with metastatic esophagogastric…”
Get full text

Ramucirumab, avelumab, and paclitaxel (RAP) as second-line treatment in gastro-esophageal adenocarcinoma, a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO) by Thuss-Patience, Peter C., Högner, Anica, Goekkurt, Eray, Stahl, Michael, Kretzschmar, Albrecht, Schädlich, Bärbel, Goetze, Thorsten Oliver, Stocker, Gertraud, Reichardt, Peter, Kullmann, Frank, Pink, Daniel, Bartels, Prisca, Ballhausen, Alexej, Jarosch, Armin, Hinke, Axel, Binder, Mascha, Stein, Alexander

“…4051 Background: Combination of ramucirumab and paclitaxel is a standard second line therapy in gastro-esophageal adenocarcinoma (GEAC) (RAINBOW trial, Wilke…”
Get full text

Pazopanib with 5‐FU and oxaliplatin as first line therapy in advanced gastric cancer: A randomized phase‐II study—The PaFLO trial. A study of the Arbeitsgemeinschaft Internistische Onkologie AIO‐STO‐0510 by Högner, Anica, Al‐Batran, Salah‐Eddin, Siveke, Jens T., Lorenz, Mario, Bartels, Prisca, Breithaupt, Kirstin, Malfertheiner, Peter, Homann, Nils, Stein, Alexander, Gläser, Dietrich, Tamm, Ingo, Hinke, Axel, Vogel, Arndt, Thuss‐Patience, Peter

“…VEGF inhibition in gastric cancer has a proven benefit in the second line setting. Pazopanib, an oral tyrosine kinase inhibitor, selectively inhibits VEGFR‐1,…”
Get full text

Ramucirumab, Avelumab, and Paclitaxel as Second-Line Treatment in Esophagogastric Adenocarcinoma: The Phase 2 RAP (AIO-STO-0218) Nonrandomized Controlled Trial by Thuss-Patience, Peter, Högner, Anica, Goekkurt, Eray, Stahl, Michael, Kretzschmar, Albrecht, Götze, Thorsten, Stocker, Gertraud, Reichardt, Peter, Kullmann, Frank, Pink, Daniel, Bartels, Prisca, Jarosch, Armin, Hinke, Axel, Schultheiß, Christoph, Paschold, Lisa, Stein, Alexander, Binder, Mascha

“…Adding immune checkpoint inhibitors to chemotherapy has been associated with improved outcomes in metastatic esophagogastric adenocarcinoma, but treatment…”
Get full text